Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

DOI: 10.3390/cancers11060872

Keywords: cancer, immune checkpoint, PD-1, PD-L1, single domain antibody, nanobody, monoclonal antibody, avelumab, immunotherapy, T cell

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text